Last updated on September 2020

Treatment Resistance Following Anti-cancer Therapies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Disease Progression
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors treated as follows:
  • Non small cell lung carcinoma (NSCLC) monotherapy: Disease progression (PD) on 1st line monotherapy anti PD-1/ L1.
  • NSCLC combination: PD on 1st line anti PD-1/ L1 plus standard doublet platinum containing regimen; or PD on 1st-line anti-PD-1/-L1 plus standard doublet platinum-containing regimen followed by continuation of single agent anti-PD-1/-L1).
  • Renal cell carcinoma (RCC) with clear cell component: PD on 2nd line monotherapy anti PD-1/ L1; or PD on 1st line combination of doublet anti-PD-1/ L1 with anti-CTLA-4; or PD on 1st-line combination of avelumab with axitinib or pembrolizumab with axitinib.
  • HR+ HER2 adenocarcinoma of the breast: PD on 1st line combination of doublet palbociclib with hormonal therapy.
  • Castrate resistant adenocarcinoma of the prostate: PD on enzalutamide monotherapy.
  • Castrate resistant adenocarcinoma of the prostate: PD on abiraterone in combination with prednisone.
  • germline mutated BRCA (gBRCAm), HER2- breast cancer: PD on a PARP inhibitor monotherapy in patients previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
  • Radiographic evidence of PD, including the target lesion being subjected to biopsy for the study, on the most recent regimen that requires a change in anti-cancer treatment.

Exclusion Criteria:

  • Tumor biopsy taken from a bone or an irradiated target lesion.
  • Discontinuation of current or most recent anti cancer therapy due to toxicity and not progressive disease.
  • Initiation of new anti-cancer therapy after disease progression prior to planned biopsy.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.